Last reviewed · How we verify
NCT04830826: ADDRESS
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
trial testing Surgeries in NSCLC, Stage I in 1,490 participants. Completed in 7 April 2025.
8 July 2024
Quick facts
| Lead sponsor | The First Affiliated Hospital of Guangzhou Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,490 |
| Start date | 9 July 2020 |
| Primary completion | 8 July 2024 |
| Estimated completion | 7 April 2025 |
| Sites | 51 locations across China |
Drugs / interventions tested
- Surgeries
Conditions studied
- NSCLC, Stage I — all drugs for NSCLC, Stage I →
- NSCLC, Stage II — all drugs for NSCLC, Stage II →
- NSCLC, Stage III — all drugs for NSCLC, Stage III →
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Who can join
Eligibility, any sex, with NSCLC, Stage I or NSCLC, Stage II. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, national, multi-center, non-interventional study. The main purpose is to explore the initial adjuvant treatment pattern after radical resection for early-stage NSCLC patients with EGFR Mutation-Positive in the real world. The secondary purpose was to observe the postoperative follow-up treatment pattern and its subgroups (based on different EGFR mutation status and different clinical stages).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeted therapy for stage IA non-small cell lung cancer with <i>EGFR</i> mutations: a scoping review.
Xie Y, Xia L, Niu Z, Zhang X, et al · · 2026 · PMID 42170287 · DOI 10.21037/tlcr-2025-aw-1251
Verify or expand the search:
- PubMed search for NCT04830826
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Surgeries
Trials testing the same drug.
- NCT03710616 — A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals · unknown
- NCT03427541 — A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases · unknown
- NCT03415815 — An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer · unknown
- NCT03451526 — A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer · completed
- NCT03413956 — An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer · completed
Other recruiting trials for NSCLC, Stage I
Currently open trials in the same condition.
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT06467383 — A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced · recruiting
- NCT05686434 — Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) · Phase 2 · recruiting
- NCT06404164 — Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection · NA · recruiting
- NCT04317534 — Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With P · Phase 2 · recruiting
Other The First Affiliated Hospital of Guangzhou Medical University trials
Trials by the same sponsor.
- NCT07413952 — Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases · Phase 2 · not yet recruiting
- NCT07395375 — Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection · NA · not yet recruiting
- NCT07395362 — Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules · NA · not yet recruiting
- NCT07395349 — Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection · NA · not yet recruiting
- NCT07377916 — Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04830826 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Guangzhou Medical University
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04830826.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing